Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.22 USD | +1.07% | -1.51% | -11.36% |
14/05 | Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target | MT |
10/05 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
End-of-day quotes
Sector Bio Therapeutic Drugs
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
6.11B | ||||||
111B | ||||||
106B | ||||||
22.24B | - | |||||
21.25B | - | |||||
18.97B |
- Stock Market
- Equities
- EXEL Stock
- Charts Exelixis, Inc.
- Sector Chart